Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
President & CEO | Nektar TherapeuticsNKTR | Open-market sale10b5-1 plan | 06/16–06/17 | 06/18 | 20,000 sh4 trades | $60.75avg. | $1,215,055.78 | −26.7% |
Zalevsky JonathanChief R&D Officer | Nektar TherapeuticsNKTR | Open-market sale10b5-1 plan | 06/15 | 06/17 | 5,538 sh | $60.71 | $336,211.98 | −26.4% |
Robin Howard W.President & CEO | Nektar TherapeuticsNKTR | Open-market sale | 05/19 | 05/21 | 444 sh | $65.51 | $29,086.44 | −0.6% |
Zalevsky JonathanChief R&D Officer | Nektar TherapeuticsNKTR | Open-market sale | 05/19 | 05/21 | 199 sh | $65.51 | $13,036.49 | −0.9% |
Robin Howard W.President & CEO | Nektar TherapeuticsNKTR | Open-market sale | 02/18 | 02/20 | 423 sh | $73.00 | $30,879 | −0.6% |
Zalevsky JonathanChief R&D Officer | Nektar TherapeuticsNKTR | Open-market sale | 02/18 | 02/20 | 180 sh | $73.00 | $13,140 | −0.8% |
Zalevsky JonathanChief R&D Officer | Nektar TherapeuticsNKTR | Open-market sale10b5-1 plan | 01/20 | 01/22 | 3,867 sh | $35.67 | $137,935.89 | −15.3% |
Robin Howard W.President & CEO | Nektar TherapeuticsNKTR | Open-market sale | 25/11/25 | 25/11/25 | 2,207 sh | $54.28 | $119,795.96 | −3.9% |
Zalevsky JonathanChief R&D Officer | Nektar TherapeuticsNKTR | Open-market sale | 25/11/25 | 25/11/25 | 1,157 sh | $54.28 | $62,801.96 | −5.7% |
Wilson Mark AndrewChief Legal Officer | Nektar TherapeuticsNKTR | Open-market sale | 25/11/25 | 25/11/25 | 630 sh | $54.28 | $34,196.4 | −2.8% |
President & CEO | Nektar TherapeuticsNKTR | Open-market sale10b5-1 plan | 25/09/09 | 25/09/11 | 6,666 sh4 trades | $46.69avg. | $311,214.24 | −11.9% |
President & CEO | Nektar TherapeuticsNKTR | Open-market sale10b5-1 plan | 25/09/04–25/09/05 | 25/09/08 | 11,832 sh7 trades | $36.42avg. | $430,958.59 | −17.4% |
Chief R&D Officer | Nektar TherapeuticsNKTR | Open-market sale10b5-1 plan | 25/09/04 | 25/09/08 | 1,721 sh4 trades | $33.52avg. | $57,692.51 | −9.0% |
Robin Howard W.President & CEO | Nektar TherapeuticsNKTR | Open-market sale10b5-1 plan | 25/09/02 | 25/09/04 | 1,500 sh | $30.16 | $45,240 | −2.2% |
Zalevsky JonathanChief R&D Officer | Nektar TherapeuticsNKTR | Open-market sale10b5-1 plan | 25/09/02 | 25/09/04 | 485 sh | $30.10 | $14,598.5 | −2.5% |
Robin Howard W.President & CEO | Nektar TherapeuticsNKTR | Open-market sale | 25/08/19 | 25/08/21 | 1,573 sh | $26.59 | $41,826.07 | −2.2% |
Zalevsky JonathanChief R&D Officer | Nektar TherapeuticsNKTR | Open-market sale | 25/08/19 | 25/08/21 | 725 sh | $26.59 | $19,277.75 | −3.6% |
Wilson Mark AndrewChief Legal Officer | Nektar TherapeuticsNKTR | Open-market sale | 25/08/19 | 25/08/21 | 676 sh | $26.59 | $17,974.84 | −3.2% |
Robin Howard W.President & CEO | Nektar TherapeuticsNKTR | Open-market sale | 25/05/19 | 25/05/21 | 23,208 sh | $0.67 | $15,549.36 | −2.1% |
Zalevsky JonathanChief R&D Officer | Nektar TherapeuticsNKTR | Open-market sale | 25/05/19 | 25/05/21 | 10,712 sh | $0.67 | $7,177.04 | −3.4% |
